Have an account? Log in.
I don't have an account.
Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, ALERT trial success, and analyst ratings.
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average up 0.58% at 48,185.80.
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (NASDAQ:GILD) aimed at
Tempus AI says ALERT trial shows higher valve procedures and faster care, while analysts keep a Buy rating with varied price targets.
ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease and accelerate
Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and lowers the price target from $95 to $60.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.